# Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

> **NCT00818753** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 53 (actual)

## Conditions studied

- Heart Catheterization

## Interventions

- **DRUG:** dabigatran 110 mg
- **DRUG:** dabigatran 150 mg
- **DRUG:** unfractionated heparin

## Key facts

- **NCT ID:** NCT00818753
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818753, "Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00818753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*